Facebook and Nasdaq STILL BATTLING and 3 Headlines Investors are Watching Now

NASDAQ (NASDAQ:NDAQ) continues to be in danger of losing Facebook (NASDAQ:FB), its trophy listing, to the NYSE (NYSE:NYX) as the company continues to place the blame for its botched IPO at Nasdaq’s door, reports the NYT. Nasdaq CEO Robert Greifeld didn’t exactly soothe ruffled feathers by claiming on a conference call that the problems on his exchange did not affect Facebook’s stock price.

Don’t Miss: Will Facebook’s Next Earnings Report SINK or SWIM?

Ampio Pharmaceuticals (AMPE) has entered a deal to manufacture Zertane-ED, a combination drug that addresses male sexual dysfunctions, with India’s Syngene and shares take off after the announcement. Daewoong, AMPE’s Korean partner, will finance and conduct the Phase 3 trials of the product in South Korea.

ATP Oil & Gas‘ (NASDAQ:ATPG) Shimson well, located off the coast of Israel in a water depth of 3,622 feet and drilled to a subsea depth of 14,445 feet, has hit more than 62 feet of natural gas pay. More information on the well is expected during Q3, shares in the meanwhile take off.

Corcept Therapeutics (NASDAQ:CORT), which develops drugs for treating psychiatric and metabolic disorders such as Cushing’s Syndrome and psychotic depression, will raise funds for R&D and other expenses via an issue of 11 million shares.

Don’t Miss: The Week Ahead on Wall Street: Short Holiday Week, BLS Unemployment.